Tegoprazan, a next‑gen potassium‑competitive acid blocker, launches in India via Dr. Reddy's partnership with support.

• Provides fast onset, prolonged gastric pH control, improving treatment for GERD, NERD, and ulcers effectively.
• Approved in 21 countries, including South Korea and China, and completed the US Phase‑III trial successfully.
• Collaboration merges Dr. Reddy's market strength with HK Inno. N's innovation, expanding patient access in India.